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Serum and urinary levels of beta human chorionic gonadotrophin in
patients with transitional cell carcinoma
J. McLoughlin, T. Pepera, J. Bridger & G. Williams
Department ofSurgery, Hammersmith Hospital, Du Cane Road, London W12 OHS, UK.
Summary Serum and early morning urine specimens were obtained from 62 patients. The levels of beta
human chorionic gonadotrophin (BhCG) in both serum and urine were estimated simultaneously in all cases.
At the time of estimation 43 patients had transitional cell carcinoma of the bladder, one had transitional cell
carcinoma of the renal pelvis and three had carcinoma in situ (two ofwhom also had overt carcinoma). Raised
serum and urinary levels were found in only three patients, all ofwhom had poorly differentiated or metastatic
transitional cell carcinoma of the bladder. This observation is in accordance with previous studies. In one of
these patients, who underwent transurethral resection of her bladder tumour, the urinary levels returned to
within normal limits post resection. An additional three patients had elevations of serum BhCG. Two of these
three patients had poorly differentiated transitional cell carcinoma present at the time of estimation and one
had no sign of recurrence. Using immunoperoxidase staining a retrospective study was undertaken to stain all
available sections belonging to patients studied to observe whether BhCG was being produced by the
respective tumours. Twelve well differentiated, nine moderately well differentiated and seven poorly differ-
entiated specimens were available. In no case was evidence of BhCG production demonstrated in these
tumours despite its presence being demonstrable in positive controls. We confirm the production of BhCG
associated with bladder tumours, a feature correlated with poorer differentiation. Studies employing larger
patient numbers are necessary to clarify the role of this tumour marker in patients with well differentiated
bladder tumours.
The production of human chorionic gonadotrophin (hCG)
by non trophoblastic tumours has been demonstrated by a
series of observers (Braunstein et al., 1973; McManus et al.,
1976; Iles et al., 1987). Shah et al. (1986) identified sites of
BhCG production in the cytoplasm of cells in high-grade
bladder tumours using immunoperoxidase staining techni-
ques. Dexeux et al. (1986) found that serum BhCG levels
were elevated in 30% of cases with advanced bladder cancer
and when elevated by greater than 50% than normal cor-
related well with the clinical course. Fukutami et al. (1983)
demonstrated elevated levels of BhCG in the urine ofpatients
with a range ofurological malignancies including three out of
12 patients with transitional cell carcinomas.
Recently it was postulated that the secretion of hCG and
its beta subunit (BhCG) was an innate property of bladder
epithelium, whether it be neoplastic or non neoplastic (Iles et
al., 1987). This would suggest that BhCG levels may be
measurable in the serum and urine of patients with tumours
of better differentiation.
The present study was undertaken to assess the merit of
using BhCG levels as a tumour marker in bladder cancer.
Materials and methods
A serum and an early morning urine sample were obtained
from 57 patients prior to undergoing diagnostic or check
cystoscopy. An additional five patients with advanced or
metastatic, poorly differentiated bladder cancer who were
referred for consideration for systemic chemotherapy were
similarily studied. All BhCG estimations were made at Char-
ing Cross Cancer Research Campaign laboratories. A radio-
immunoassay technique using a polyclonal antibody of rabbit
origin directed against Beta subunit of hCG was employed
(sensitive to a level of approximately 1 IU/1-1). This assay
reacts with the Beta core fragment, the free Beta subunit and
also the Beta component of the intact hCG molecule. Speci-
mens were analysed in batches and stored at 4°C. Merthiolate
was added to urine specimens prior to storage. Details of the
patient's age, sex, menopausal status and drug history were
noted. The current T category, histological grade of the
tumour, date of first diagnosis, previous management and
tumour behaviour were also recorded. The upper limit of
normal for non pregnant adult males and females was taken
as 5 IU 1'-I of BhCG in serum and 5 IU [1-I in urine. Histo-
logical specimens were obtained from the histopathology
department and unstained 3 tsm paraffin wax sections were
taken off representative sections of the bladder tumour, all
tissues having been previously formalin fixed prior to tissue
processing. Sections were processed and stained in accor-
dance with the technique described by Shah et al. (1986).
Rabbit anti-human chorionic gonadotrophin (Dakopatts),
diluted 1; 20, was applied for 30min followed by rabbit
peroxidase - antiperoxidase (1: 100) for 30min. This anti-
body recognises the intact hCG molecule, the beta subunit
alone and also the beta subunit in combination with the
intact molecule (M. Nilsson, Dakopatts, Personal Commun-
ication). Placental sections were used as positive controls.
Results
Sixty-two patients, 41 male and 21 female, were studied. All
but one of the female patients were post menopausal. Fifteen
patients had well differentiated, 14 moderately well and 15
poorly differentiated transitional cell carcinoma of the blad-
der at the time of BhCG estimation. Four patients had areas
of squamoid differentiation in their specimens. Three patients
had carcinoma in situ (two ofwhom also had transitional cell
carcinoma present concurrently). Two patients had metasta-
tic transitional cell carcinoma. Three of the patients with well
differentiated and two of those with moderately well differ-
entiated bladder tumours had extensive intravesical disease
whilst three of those with poorly differentiated tumour had
extravesical spread. Of the 44 patients with transitional cell
carcinoma, 43 were of the bladder and one of the renal
pelvis. Seventeen patients had no sign of recurrence and of
these four had previously undergone radiotherapy and two
systemic chemotherapy for poorly differentiated carcinomas.
Seventeen patients had no sign of recurrence at the time of
BhCG estimation.
Three patients had both elevated serum and urinary levels
of BhCG (serum levels were 8, 10 and 21 IU l-I and urinary
levels 29, 36 and 168 IU 1' respectively) (Figure 1). All three
had poorly differentiated transitional cell carcinoma. One of
these patients had metastatic bladder cancer, one extensive
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extravesical spread and one a locally resectable poorly differ-
entiated malignancy. In this last patient the urinary levels of
BhCG fell to within normal limits on estimation 2 weeks
after resection of her bladder tumour.
A further three patients had elevations of BhCG in their
serum alone (Figure 1). Two of these had poorly different-
iated tumours (serum levels of 6 and 8 IU/1'I respectively)
but the third had no sign of recurrence at the time of
estimation (serum level 19 IU 1'). This last patient had
previously had regular well differentiated recurrences.
Immunoperoxidase staining of 28 sections and was per-
formed. Twelve of these sections had evidence of well differ-
entiated tumour present. Nine moderately well differentiated
tumour and seven poorly differentiated transitional cell car-
cinomas present. Two of the specimens had evidence of
carcinoma in situ (one of which also had a moderately well
differentiated bladder tumour present in the same section).
None of the tissues, including one of the patients with
elevated urinary and plasma level of BhCG and the two
patients who had tumour recurrence with raised serum levels
of BhCG showed evidence of BhCG production. Applying
the same technique to the controls (placental tissue) all
stained positive for BhCG.
Follow up ranges from 11-17 months (mean 14). Of the
patients with elevated serum and urinary levels of BhCG two
failed to respond to chemotherapy and one has died from
metastatic disease. Two of the three patients with elevation
of serum levels alone were managed by chemotherapy and
have to date remained clear of any recurrence. The third
patient (who was noted to have an elevated BhCG level, but
no recurrence) has developed further recurrence on two of
three occasions following this time.
Discussion
In this study, three of the 15 patients (20%) with poorly
differentiated transitional cell carcinomas had both raised
serum and urinary levels of BhCG. This compares to the
report of Dexeus et al. (1986) who demonstrated that 38% of
patients with advanced transitional cell carcinoma of the
bladder had some degree of elevation of BhCG in their
serum.
Using immunoperoxidase staining both Shah et al. (1986)
and Rodenburg et al. (1985) observed BhCG production in
poorly differentiated tumours and it has been suggested that
a process of tumour de-differentiation was responsible for the
production of BhCG (Shah et al., 1986). Iles et al. (1987)
however were able to demonstrate BhCG production in both
neoplastic and non neoplastic cell lines suggesting that BhCG
secretion is an innate property of bladder epithelium. It was
on the basis of this that our investigation was performed,
evaluating a range of tumours to assess whether levels were
elevated in any cases of low grade tumours. Our results show
that serum levels were not elevated in any case of well or
moderately well differentiated bladder tumour.
Fukutami et al. (1983) demonstrated elevated urinary
levels of BhCG in two of 10 patients with bladder carcinoma.
A possible advantage of a urinary assay is that some tumours
produce immunoreactive BhCG like substances (urinary gon-
adotrophin fragments) which, by virtue of subtle differences
in their carbohydrate chains, may be rapidly cleared by the
kidneys so that serum levels do not accumulate. It has been
suggested that in urinary estimation of these substances may
be a more reliable reflection of secretion (Nam et al., 1990).
In addition, in view of the fact that the bladder tumour is the
direct site of production of the BhCG (Iles et al., 1987; Shah
et al., 1986; Rodenburg et al., 1985) it could be expected that
the highest levels would be found in the urine. In this study
however no patient was observed to have an elevated early
morning urinary BhCG level in the presence of a serum level
within the normal range.
In three cases serum levels alone were elevated. Two of
these patients had grade 3 tumours (serum levels of 6 and
8 IU 1-l) present but one had no sign of recurrence at the
time of estimation (serum level 19 IU 1'). The significance of
these results is unclear. In the two cases where tumour
recurrence was noted and resected staining of the specimens
revealed no evidence of BhCG production in the sections
examined. Fukutami et al. (1983) suggested that greater sen-
sitivity of assessing urinary BhCG levels could be obtained
by estimating the 24 h urinary excretion of BhCG especially
where serum levels are equivocal. The prospective nature of
this study however precluded a retrospective estimation of
24 h urinary secretion in these patients as they had under-
gone tumour resection by the time their levels were available.
In the sections examined 12 had well, nine had moderately
well and seven had poorly differentiated bladder tumour
present. These sections included both of the patients who had
elevated serum levels with tumour present (one patient with
raised serum level had no sign of recurrence) but unfor-
tunately only one of the three cases with raised serum and
urinary levels of BhCG.
Shah et al. (1986) observed that the production of BhCG is
often very localised and our negative result could reflect
sampling error of the sections obtained. Alternatively the
immunohistochemical method may be less sensitive than the
polyclonal assay (which recognises the beta HCG core frag-
ment). For example, techniques measuring B subunit core
fragments have been shown to be of greater sensitivity than
those estimating only free B subunits in patients with gynae-
cological malignancies (Cole et al., 1988). The fact that the
urinary levels fell rapidly following resection of the bladder
tumour would suggest that the tumour was actually produc-
ing BhCG. Our positive controls were all positive suggesting
that our lack of staining was not due to poor technique. In
the other two cases, the patients had been referred for con-
sideration for chemotherapy from other hospitals and no
sections were available. (Formal histology reports were avail-
able and confirmed the presence of pooly differentiated tran-
sitional cell carcinoma of the bladder.)
From the results of this study BhCG would appear to be
produced by only tumours of poorer differentiation and as
such, measurement of BhCG as a tumour marker could be
expected to have only a limited role in well or moderately
well differentiated bladder tumours. Further studies, using
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